Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, B-Cell 17Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Non-Hodgkin 12Recurrence 11Burkitt Lymphoma 10Multiple Myeloma 7Lymphoma 7Neoplasms 6Leukemia, Myeloid, Acute 6Lymphoma, Mantle-Cell 5Leukemia 5Pancreatic Neoplasms 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm, Residual 3Nasopharyngeal Carcinoma 3Leukemia, B-Cell 3Glioma 3Colorectal Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Simpson-Golabi-Behmel syndrome 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Melanoma × Immunotherapy, Adoptive × Clear all
NCT02354690 2020-03-23

Vemurafenib and TIL Therapy for Metastatic Melanoma

Herlev Hospital

Phase 1/2 Completed
13 enrolled 12 charts
Dermatologic

Melanoma

NCT00324623 2012-11-20

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

Centre Hospitalier Universitaire Vaudois

Phase 1 Completed
8 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡